Statin therapy for vascular failure

Cardiovascular Drugs and Therapy

Volumn 21, Issue 4, 2007, Pages 281-295

  Inoue, Teruo ^a   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary artery disease; Inflammation; Oxidative stress; Pleiotropic effect; Statin; Vascular endothelial function; Vascular failure; Vascular smooth muscle function

Indexed keywords

ACETYLCHOLINE; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; STROKE; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUSCLE, SMOOTH, VASCULAR; RISK FACTORS;

EID: 34548597220     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6038-y     Document Type: Review

References (129)

1. Inoue T, Node K. Vascular failure-a new clinical entity for vascular disease. J Hypertens 2006;24:2121-30.
2. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipid levels on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 2001;38:56-63.
6. Sacks FM, Pfeffer MA, Moye' L, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991;68:1436-46.
7. Mikhaildis DP, Wierzbiki AS, Reynolds TM. Is a mechanical or metabolic approarch superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. Eur Heart J 2001;22:972-3.
8. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-9.
9. Serruys PW, de Feyter P, Macaya C, et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
10. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomized controlled trial. Lancet 2006;368:1155-63.
11. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997;20:3-10.
12. Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. Circulation 1992;86:III12-9.
13. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999;34:631-8.
14. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719.
15. Wilson SH, Simari RD, Best PJM, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:172-8.
16. Bonetti PO, Wilson SH, Rodriguez-Porcel M, et al. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 2002;40:546-54.
17. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-91.
18. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
19. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res 1983;53:984-9.
20. Vanhoutte PM, Rimele TJ. Role of endothelium in the control of vascular endothelial function. J Physiol (Paris) 1983;78:681-9.
21. Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelial dysfunction in angigraphically normal coronary arteries of patients with coronary artery disease. Circulation 1989;79:287-91.
22. Horio Y, Yasue H, Rokutanda M, et al. Effects of intracoronary injection of acetylcholine on coronary artery diameter. Am J Cardiol 1986;57:984-9.
23. Yasue H, Omote S, Takizawa A, et al. Coronary arterial spasm in ischemic heart disease and its pathogenesis: a review. Circ Res 1983;52:I147-52.
24. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardivasc Pharmacol 2002;39:319-27.
25. Egashira K, Inou T, Hirooka K, et al. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiogram. Circulation 1994;89:2519-24.
26. Inoue T, Sakai Y, Morooka S, et al. Vasodilatory capacity of coronary resistance vessels in dilated cardiomyopathy. Am Heart J 1994;127:376-81.
27. Wu HD, Katz SD, Beniaminovitz A, et al. Assessment of endothelium-mediatedvasodilation of the peripheral circulation by transcutaneous ultrasonography and venous occlusion plethysmography. Heart Vessels 1999;14:143-8.
28. Higashi Y, Yoshizumi M. New method to evaluate endothelial function: method for assessing endothelial function in humans using a strain-gauge plethysmography: nitric oxide-dependent and-independent vasodilation. J Pharmacol Sci 2003;93:399-404.
29. Olsen SP, Clapham DE, Davis PF. Hemodynamic shear stress activates a K+ current in endothelial cells. Nature 1998;331:168-70.
30. Takase B, Hamabe A, Satomura K, et al. Close relationship between the vasodilator response to acetylcholine in the brachial and coronary artery in suspected coronary artery disease. Int J Cardiol 2005;105:58-66.
31. Inoue T, Hayashi M, Takayanagi K, Morooka S. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low-density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 2002;160:369-76.
32. Jarvisalo MJ, Toikka JO, Vasankari T, et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999;147:237-42.
33. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
34. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
35. Halcox JPJ, Schenche WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
36. Particone F, Ceravolo R, Pujia A, et al. Prognostic significance of endeothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
37. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
38. Gokce N, Kerney JF Jr, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72.
39. Higashi Y, Sasaki S, Nakagawa K, et al. Excess norepinephrine impairs both endothelium-dependent and -independent vasodilation in patients with pheochromocytoma: a comparison before and after adrenalectomy. Hypertension 2002;39:513-8.
40. Bergdahl A, Persson E, Hellstrand P, Sward K. Lovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery. Pharmacol Toxicol 2003;93:128-34.
41. Holaj R, Spacil J, Petrasek J, Malik J, Haas T, Aschermann M. Intima-media thickness of the common carotid artey is the significant predictor of angiographically proven coronary artery disease. Can J Cardiol 2003;19:670-6.
42. Matsushima Y, Kawano H, Koide Y, et al. Relationship of carotid intims-media thickness, pulse wave velocity, and ankle brachial index to the severity of coronary artery atherosclerosis. Clin Cardiol 2004;27:629-34.
43. Kablak-Ziembicka A, Tracz W, Przewlocki T, Pieniazek P, Sokolowski A, Konieczynska M. Association of increased carotid intima-media thickness with the extent of coronary artery disease. Heart 2004;90:1286-90.
44. Hallerstam S, Larsson PT, Zuber E, Rosfors S. Carotid atherosclerosis is correlated with extent and severity of coronary artery disease evaluated by myocardial perfusion scintigaphy. Angiology 2004;55:281-8.
45. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.
46. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;9256:577-81.
47. Nishioka H, Shimada K, Kataoka T, et al. Impact of HMG-CoA reductase inhibitors for non-treated coronary segments. Osaka City Med J 2004;50:61-8.
48. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
49. Lusis AJ. Atherosclerosis. Nature 2004;407:233-41.
50. Shishehbor MH, Bhatt DL. Inflammation and atherosclerosis. Curr Atheroscler Rep 2004;6:131-9.
51. Schönbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000;97:7458-63.
52. Henn V, Slupsky JR, Grafe M. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
53. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovasc Dis 2002;44:349-56.
54. Ott I, Newmann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996;94:1239-46.
55. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-8.
56. Toutouzas K, Colombo A, Srefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004;25:1679-87.
57. Welt FGP, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22:1769-76.
58. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003;107:1757-63.
59. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
60. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-72.
61. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
62. Inoue T, Kato T, Uchida T, et al. C-reactive protein is derived from inflammatory vulnerable plaque in acute coronary syndrome. J Am Coll Cardiol 2005;46;239-45.
63. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation. J Am Coll Cardiol 2002;40:1935-42.
64. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997;17:1521-6.
65. Pruefer D, Scalia R, Lefer AM. Sinvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999;19:2894-900.
66. Wojciak-Stothard B, Williams L, Ridly AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol 1999;145:1293-307.
67. Kwak BR, Mach F. Statins inhibit leukocyte recruitment-new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001;21:1256-9.
68. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-75.
69. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isilated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-7.
70. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
71. Yoshida M, Sawada T, Ishii H. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001;21:1165-71.
72. Weitz-Schmidt G, Kamata T, Kallen J, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.
73. Ikeda U, Ito T, Shimada K. Statins and C-reactive protein. Lancet 1999;353:1274-5.
74. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor as an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferators-activated receptor α PPARα) in primary endothelial cells. Life Sci 2000;67:863-76.
75. Diamonde L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001;21:1327-32.
76. Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001;159:27-33.
77. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
78. Katzneison S, Wang XM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998;17:335-40.
79. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001;69:959-62.
80. Bellosta S, Via D, Canavesi P, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion my macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
81. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
82. Nawawi H, Osman NS, Yusoff K, Khalid BA. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 2003;35:479-85.
83. Matsuoka H. Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Pract 2001;54:S65-72.
84. Harrison DG. Cellular and molecular mechanism of endothelial cell dysfunction. J Clin Invest 1997;100:2153-7.
85. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J Biol Chem 1997;272:20963-6.
86. Fogelman AM, Schechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipo-proteins leads to cholesterol ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980;77:2214-8.
87. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherosclerosis. Proc Natl Acad Sci USA 1987;84:2995-8.
88. Inoue T, Hayashi M, Takayanagi K, Morooka S. Oxidative DNA damage is induced by chronic cigarette smoking, but repaired by abstension. J Health Sci 2003;29:217-20.
89. Palinski W, Ylä-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-35.
90. Inoue T, Inoue K, Maeda H, Takayanagi K, Morooka S. Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL concentrations in dyslipidemic patients. Clin Chim Acta 2001;305:115-21.
91. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol 2001;37:1871-6.
92. Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
93. Bergmark C, Wu R, de Faire RW, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidzed LDL. Arterioscler Thromb Vasc Biol 1995;15:441-5.
94. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001;37:775-9.
95. Wilson SH, Simari RD, Best PJM, et al. Sinvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:122-8.
96. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
97. Wassmann S, Laufs U, Bäumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
98. Wassmann S, Laufs U, Müller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-5.
99. Girona J, La Ville AE, Sota R, Plana N, Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846-51.
100. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interaction of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998;31:39-45.
101. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H, Suzuki T. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, an HMG-CoA redactase inhibitor. Chem Pharm Bull 1999;47:1010-2.
102. Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsome. Eur J Pharmacol 1998;361:143-9.
103. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;154:87-96.
104. Inoue T, Takayanagi K, Hayashi T, Morooka S. Fluvastatin attenuate nitrate tolerance in patients with ischemic heart disease. Int J Cardiol 2003;90:181-8.
105. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statin-implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
106. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31:2437-49.
107. Kearney D, Fitzgerald D. The anti-thrombotic effects of statins. J Am Coll Cardiol 1999;33:1305-7.
108. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997;17:265-72.
109. Bourcier T, Libby P. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:556-62.
110. Essig M, Nguyen G, Prie D, Escoubet B, Sraer DJ, Friedlander G. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. A role of geranylgeranylation and Rho properties. Circ Res 1998;83:683-90.
111. Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature 2000;407:249-57.
112. Yancopoulous GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
113. Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibition: contribution to its anti-angiogenic effect. FEBS Lett 2001;495:155-9.
114. Wilson SH, Hermann J, Lerman LO, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002;105:415-8.
115. Semenza GL. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 2001;108:39-40.
116. Blann AD, Belgore FM, Constans J, Conti C, Lip GY. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or ferofibrate. Am J Cardiol 2001;87:1160-3.
117. Motoyama K, Fukumoto S, Koyama H, et al. SREBP inhibits VEGF expression in human smooth muscle cells. Biochem Biophys Res Commun 2006;342:354-360.
118. Vasa M, Fichischerer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90.
119. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI-3 kinase/Akt pathway. J Clin Invest 2001;108:391-7.
120. Lievadot J, Satoshi M, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405.
121. Forman MB, Puett DW, Virmani R. Endothelial and myocardial injury during ischemia and reperfusion: pathogenesis and therapeutic implication. J Am Coll Cardiol 1989;13:450-9.
122. Tsao PS, Aoki N, Lefer DJ, Johnson G 3rd, Lefer AM. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990;82:1402-12.
123. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:363-76.
124. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983;111:98-111.
125. Denapoli P, Antonio Taccardi A, Grilli A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001;51:283-93.
126. Laufs U, Kilter M, Kondo C, Wassmann S, Bohm M, Nickenig G. Impact of HMG-CoA reductase inhibition on small GTPases in the heart. Cardiovasc Dis 2002;53:911-20.
127. Takemoto M, Node K, Nakagami H, et al. Statins as anti-oxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-37.
128. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.
129. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.